ClinicalTrials.gg
RecruitingNCT06889545PREFASUpdated Jul 22, 2026

Comparison of Preoperative Frailty Assessment Tools

An observational study in Frailty, Frailty in Older Adults and Frailty/Sarcopenia, sponsored by Universitätsklinikum Hamburg-Eppendorf. Recruiting at 1 site in Germany. Open to participants aged 70 Years and older. Per ClinicalTrials.gov, last updated 2026-07-22.

Sponsored by Universitätsklinikum Hamburg-Eppendorf · Observational

How we know

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
584
Ages
70 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 33 studies in Frailty with a site in Germany — 7 open to participants now, 7 under way, none of them phase 3. Frailty · Germany.

Planned enrollment
8th of 20
584 · median 203
Started
2025
with 2 others
Observational
20 of 33
6 open now
Registered
30th of 33
by date
Lead sponsor
3 of 33
Universitätsklinikum Hamburg-Eppendorf

Among the 33 studies in Frailty with a site in Germany, this one is the 8th largest by planned enrollment of the 20 observational ones that give a count, is one of 3 that started in 2025, is one of 20 observational ones, and was the 30th registered.

Frailty

1,291 studies on the registry are indexed under Frailty; 454 are open to participants now.

Browse Frailty studies →

Open to participants now

7 of the 33 studies in Frailty with a site in Germany are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 299 Frailty studies recruiting now, 235 (79%) set no upper age limit and 10 (3%) stop at 75 or younger; 7 take children under 18; 66 take healthy volunteers.

This study: 70 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies in Frailty with a site in Germany, or all of them as a file.
02

Study summary

Frailty is a significant risk factor for postoperative complications and functional decline. Preoperative assessment of frailty is therefore recommended in all older adults. However, despite the availability of many frailty tools, few have been tested in the preoperative setting and there is little comparison of their predictive value in identifying patients at risk. The aim of this study is to investigate which of the following instruments for determining frailty has the highest predictive power with regard to the occurrence of postoperative complications: Risk Analysis Index, Clinical Frailty Scale, the Groningen Frailty Indicator, the Edmonton Frail Scale and the LUCAS-FI. The aim of this research project is to identify a suitable frailty instrument for preoperative risk stratification of older patients during the premedication visit.

03

Conditions studied

  • Frailty
  • Frailty in Older Adults
  • Frailty/Sarcopenia
04

Who can participate

Ages eligible
70 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients of the Medical University Centre Hamburg, Germany

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 70 years and older
  • scheduled surgery
  • estimated time of surgery 120 Minutes or more

Exclusion criteria

Exclusion Criteria:

  • insufficient German language skills (for cognitive testing)
  • mental retardation
  • relevant psychiatric disorder (not allowing for cognitive testing)
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
584 participants (estimated)
Patient registry
No

Groups and cohorts

  • Older patients

    Patients at 70 years and above scheduled for surgery

    Other: Assessment of frailty using multiple tools

Interventions

  • OtherAssessment of frailty using multiple tools

    This is an observational study without any intervention. Frailty is assessed using multiple tools and postoperative outcome is compared.

06

What researchers measure

Primary outcomes

  1. Complications in the first 30 days after surgery

    Measured by Clavien-Dindo classification

    Time frame: 30 days

Secondary outcomes

  1. Functional state (activities of daily living)

    Measured using WHO Disability Assessment Schedule 2.0

    Time frame: one, three and six months after surgery

  2. Postoperative Quality of Recovery

    Measured by Quality-of-Recovery-15 questionnaire

    Time frame: postoperative day 2

  3. Muscle loss during hospitalisation

    measured by bioimpedance prior to admission and before discharge from hospital

    Time frame: From date of enrollment, up to 4 weeks after surgery

  4. Postoperative delirium

    Measured by 3D-Confusion Assessment Method

    Time frame: postoperative day 1 to 5

  5. Length of stay

    days spent in hospital after surgery

    Time frame: from day of surgery, up to 4 weeks after surgery

  6. Discharge destination

    e.g.:home, nursing home, other hospital

    Time frame: up to 4 weeks after surgery

  7. Cognitive state

    Using 5-Minute Montreal Cognitive Assessment (telephone-MOCA). A maximum of 15 points and a minumum of 0 points can be archieved; a higher score indicates better cognitive performance.

    Time frame: 3 and 6 months after surgery

  8. Quality-of-Life (QoL)

    Measured by WHO-Quality of Life in older adults (WHOQOL-OLD) questionnaire. The WHOQOL-OLD is evaluated by calculating scores for its six facets and summing them, with higher scores indicating a better perceived quality of life.

    Time frame: 3 and 6 months after surgery

  9. Frailty progression measured by LUCAS-FI

    Frailty assessment with Longitudinal Urban Cohort Aging Study Functional Index (LUCAS-FI)-questionnaire (telephone interview) The LUCAS-FI is evaluated by integrating both risk factors and protective resources, with the balance between them determining the degree of frailty.

    Time frame: 3 and 6 months after surgery

  10. Frailty progression measured by GFI (questionnaire)

    frailty assessment with Groningen Frailty Indicator (GFI) questionnaire (telephone interview). The GFI is evaluated by summing its item responses, with higher scores indicating a higher degree of frailty.

    Time frame: 3 and 6 months after surgery

  11. Frailty progression measured by EFS

    Frailty assessment by Edmonton Frail Scale (EFS), (score filled by physician, patient telephone interview). 1 to 10 points can be archieved, more points indicate a greater level of frailty.

    Time frame: 3 and 6 months after surgery

  12. Frailty progression by RAI measurement. The Risk Analysis Index (RAI) is evaluated by summing weighted risk factors and protective variables, with higher scores indicating greater patient vulnerability.

    Frailty assessment with Risk Analysis Index (index filled by physician, patient telephone interview)

    Time frame: 3 and 6 months after surgery

07

Study locations

1 of 1 sites recruiting
  • University Medical Centre Hamburg
    Hamburg, 22046, Germany
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided — Strict data protection guidelines prevent patient data from being made available to third parties. In specific cases, anonymised data may be provided after individual examination and consultation with the responsible ethics committee.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Nov 2027, 30 months after the start.

Of 291 non-industry observational studies under Frailty, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 55. This study's planned 30 months is close to that.

Counting every sponsor, half of 294 studies reached it within 29 months; a quarter within 12 and three quarters within 55.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 23, 2025
First posted
Mar 21, 2025
StartActual
Apr 15, 2025
Primary completionEst.
Nov 1, 2027
CompletionEst.
Apr 1, 2028
Last update
Jul 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06889545
Responsible party
Sponsor
First posted
Mar 21, 2025
Start date
Apr 15, 2025
Primary completion
Nov 1, 2027 (estimated)
Completion
Apr 1, 2028 (estimated)
Last update
Jul 22, 2026

Study contacts

Dr. Cynthia Olotu, MD
Contact
c.olotu@uke.de
0049 40 7410 52415
Dr. Cynthia Olotu, MD
principal investigator · University Medical Centre Hamburg

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion